Clinical trials: Alcoholic Liver Disease
Sensitivity to Thyroid Hormones, Metabolic Parameters
Effects of Intermittent Fasting on Fatty Liver Disease
Eighty subjects with FLD were recruited from the endocrinology clinic at Beijing Chao-yang Hospital. All of the following inclusion criteria needed to be met: hepatic fat content (HFC) were upper 5.0% evaluated by upper abdominal…
- Conditions
- Sensitivity to Thyroid Hormones, Metabolic Parameters, in Patients With FLD
- Trial name
- NCT04795973
- Testing
- 5:2 intermittent fasting
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Beijing Chao Yang Hospital
NASH - Nonalcoholic Steatohepatitis, Insulin Sensitivity
Proof of Concept ELectro-Stimulation of Muscles to resolVe Insulin Resistance in NASH
Non-alcoholic steato-hepatitis (NASH) affects up to 3% of the population and leads to liver cirrhosis, hepatocellular carcinoma (HCC) and death. The only known treatment is weight loss and exercise.
- Trial name
- ELVIS (NCT03490370)
- Testing
- Electro-muscular stimulation using NeuroTrac MyoPlus 2/4
- Where
- United Kingdom
- Volunteers
- 8 people
- Sponsor
- NHS Tayside
Alcoholic Liver Disease
Quantitative MRI for Non-invasive Assessment of Severity of Alcoholic Liver Disease (ALD)
The current goal in the treatment of Alcoholic Liver Disease (ALD) is to manage ALD-associated complications as there are no disease-specific therapies.
- Trial name
- NCT03113929
- Testing
- MRI
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- The Cleveland Clinic
Non-alcoholic Fatty Liver Disease, Diabetes
De Novo Lipogenesis, Lipid and Carbohydrate Metabolism in Non-alcoholic Fatty Liver Disease
The worldwide epidemic of obesity is paralleled with increased cases of non-alcoholic liver disease (liver fat accumulation) and diabetes.
- Trial name
- LINC (NCT00714129)
- Testing
- Dietary intervention (calorie restricted diet)
- Where
- United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Fibrosis, Liver, Type 2 Diabetes Mellitus in Obese
Semaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DM
Conduct a community intervention study that will 1) validate a screening approach to identify patients at risk for advanced NAFLD in the obese or T2DM population, and 2) test whether semaglutide treatment is effective for the…
- Conditions
- Fibrosis, Liver, Type 2 Diabetes Mellitus in Obese, Non-Alcoholic Fatty Liver Disease
- Trial name
- SAMARA (NCT06005012)
- Testing
- Semaglutide
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- University of California, San Diego
NAFLD
Effect of VLCD on the Reduction of Liver Steatosis and Fibrosis in Subjects With Obesity and NAFLD
Non-alcoholic fatty liver disease (NAFLD) is a common complication of obesity which can progress to deadly complications like end-stage liver disease and hepatocellular carcinoma.
- Trial name
- NCT04861571
- Testing
- Dietary intervention with very low calorie diet (VLCD), Control Arm
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Iowa
HBV, Alcoholic Hepatitis
Chronic Hepatitis B Virus Clinical Epidemiology in a Representative Sample of Zambian Adults
The purpose of this study is to recruit a random and representative sample of individuals within several Zambian communities for markers of Hepatitis B Virus (HBV) and to characterize chronic HBV infection and indications for…
- Conditions
- HBV, Alcoholic Hepatitis, Liver Fibroses
- Trial name
- HEP-ZED (NCT03149627)
- Testing
- Estimates - prevalence of lifetime/chronic HBV infection
- Where
- Zambia
- Volunteers
- 5,003 people
- Sponsor
- University of Alabama at Birmingham
Permeability; Increased, NAFLD
Evaluation of Gut Permeability in Patients Affected by Obesity and NAFLD: Influence of Ketogenic Diet.
This study is open label, with one arm only. In this study will be enrolled patients with obesity (BMI more than 30). Aim of the study is to determine the influence (if any) of a very low calorie ketogenic diet (VLCKD) on gut…
- Conditions
- Permeability; Increased, NAFLD, Obesity
- Trial name
- NCT05477212
- Testing
- Ketogenic Diet
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis
Fatty Liver, Nonalcoholic, Insulin Sensitivity
Determinants of Liver Fat Composition
Excessive fat in the liver, in absence of high alcohol consumption, is diagnosed as non-alcoholic fatty liver (NAFL). NAFL prevalence is as high as 50-70% in obese people and is associated with impairments in metabolic health…
- Trial name
- NCT03211299
- Where
- Netherlands
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Maastricht University Medical Center
Cirrhosis Alcoholic, Fatigue Symptom
Inflammatory and Neuroimmune Guided Investigation of Underlying Fatigue in Patients With Cirrhosis
Fatigue is a common and debilitating symptom of cirrhosis, the advanced stage of chronic liver disease. Around two-thirds of people with cirrhosis experience fatigue, which can affect their ability to carry out everyday…
- Trial name
- IGNITE (NCT07899736)
- Volunteers
- 50 people
- Sponsor
- King's College London
NASH - Nonalcoholic Steatohepatitis
LIFT Study: A Safety, Tolerability, Efficacy, and Pharmacokinetics Study of TERN-101 in Subjects With Non-Cirrhotic Non-Alcoholic Steatohepatitis (NASH)
This is a Phase 2, randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, efficacy, and pharmacokinetics (PK) of TERN-101 in non-cirrhotic NASH patients.
- Trial name
- NCT04328077
- Testing
- TERN-101
- Where
- 31 sites in United States
- Volunteers
- 101 people
- Sponsor
- Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Eating Disorders, Eating Disorder Binge
Study of Prevalence of Eating Disorder in Liver Transplant Patients
The main goal of this observational study is to measure the prevalence of binge eating disorder in liver transplant patients by evaluating the responses to the Bulimia Test.
- Conditions
- Eating Disorders, Eating Disorder Binge, Liver Transplant; Complications, Alcohol Use Disorder
- Trial name
- Pré-THETA (NCT06093919)
- Where
- 2 sites in France
- Volunteers
- 118 people
- Sponsor
- Centre Hospitalier Henri Laborit
Cirrhosis, Portal Hypertension
A Study Evaluating the Utility of Ambrisentan in Lowering Portal Pressure in Patients With Liver Cirrhosis
Endothelin is a human hormone which has been associated with increased portal pressure in patients with liver cirrhosis (also called portal hypertension). Ambrisentan blocks the effects of endothelin.
- Conditions
- Cirrhosis, Portal Hypertension, Ascites
- Trial name
- NCT03827200
- Testing
- Ambrisentan
- Where
- 6 sites in Spain
- Volunteers
- 19 people
- Sponsor
- Noorik Biopharmaceuticals AG
Diabetes, Fatty Liver
Vitamin E Pharmacokinetics and Biomarkers in Normal and Obese Women
Background: Vitamin E is an antioxidant that reduces the damaging effects of oxygen in the body. Most American men (90%) and women (96%) do not get enough vitamin E from their diets; however, the amount of vitamin E needed by the…
- Conditions
- Diabetes, Fatty Liver, Obesity, Healthy Volunteers
- Trial name
- NCT00862433
- Testing
- Alpha tocopherol, Vitamin E, Vitamin C
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Non-Alcoholic Fatty Liver Disease
Investigation on Safety and Efficacy of Soybean Fermented Extract (MBS217) in Treating Patients With NAFLD
Investigators aimed to investigate the efficacy and safety of fermented soybean extract (MBS-217) in treating participants with Non-alcoholic fatty liver disease (NAFLD) in this study.
- Trial name
- NCT05686174
- Testing
- MBS217
- Volunteers
- 30 people
- Sponsor
- National Taiwan University Hospital
Non-Alcoholic Fatty Liver Disease, Chronic Kidney Diseases
Assessment of Renal Changes in Patients With Non Alcoholic Fatty Liver Disease
Assess the renal changes in patients with non-alcoholic fatty liver (NAFLD).
- Trial name
- NCT03487068
- Testing
- The FibroScan device
- Volunteers
- 50 people
- Sponsor
- Assiut University
Non-alcoholic Fatty Liver Disease (NAFLD)
Non Alcoholic Fatty Liver Disease Influence of Statin Therapy
Aim: 1. To determine the prevalence of fatty liver in a cohort of patients hospitalized with chest pain in the Cardiology department. 2.
- Trial name
- NCT00375349
- Testing
- Ultrasound to demonstrate existence of fatty liver
- Sponsor
- Shaare Zedek Medical Center
Insulin Resistance, Hyperinsulinemia
Effect of Alpelisib in Healthy Volunteers
The goal of this clinical trial is to test a single dose of the phosphoinositide-3-kinase (PI3K) inhibitor alpelisib versus placebo in healthy volunteers.
- Conditions
- Insulin Resistance, Hyperinsulinemia, Dyslipidemias
- Trial name
- NCT05733455
- Testing
- Alpelisib 150 mg [Piqray], 2 overencapsulated tablets (total: 300 mg), FreeStyle Libre Pro, Oral glucose tolerance test (OGTT) with Trutol glucose beverage
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Columbia University
Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis
CHronic Hepatopathies Associated With ALcohol Consumption aNd metAbolic Syndrome
The aim is to determine the metabolic factors, host immune factors, and medical imaging data associated with the development of HepatoCellular Carcinoma (HCC) in patients with alcohol-related liver disease or dysmetabolic…
- Conditions
- Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis, Alcohol-related Liver Disease, Cirrhosis, Liver
- Trial name
- CHALNA2 (NCT05623150)
- Testing
- Liver biopsy
- Where
- France
- Volunteers
- 710 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Non-Alcoholic Fatty Liver Disease
Evaluating the Safety and Efficacy of Carbocisteine in the Treatment of Nonalcoholic Fatty Liver Disease Patients
Nonalcoholic fatty liver disease (NAFLD) is a global public health concern, and the leading cause of chronic liver disease, especially in developed countries.
- Trial name
- NCT06863376
- Testing
- Carbocysteine 375 MG, Physical activity, walking, and calorie restriction
- Where
- Egypt
- Volunteers
- 46 people
- Sponsor
- Tanta University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.